Breaking Out, Episode 3: Oral isotretinoin — when Accutane is the labelled door, and how the safety programme actually works

Winlevi (Episode 1) is a cream that tries to block androgen signals in the skin. Cabtreo (Episode 2) is three topicals in one pump. This episode is the oral that households still call Accutane: isotretinoin — Absorica, Absorica LD, Epuris, Clarus, Accutane, Roaccutane, and generics.

The molecule is old. The 2026 story is access. Someone said “you need Accutane.” The labelled path is: severe disease that failed conventional therapy, a clinician who knows systemic retinoids, a pregnancy-prevention programme, monthly follow-up, and a fight over who pays. Authorized is not funded. US iPLEDGE is not Canadian PEER.

Where this is taking place

This is not a 2026 trial slot. Commercial capsules are marketed in the US, Canada, the UK, the EU, and Australia. The historical US registrational comparison that still sits in the Absorica / Absorica LD label (Study 1) enrolled people 12+ with severe recalcitrant nodular acne (≥10 nodules on face and/or trunk). Canadian and US labels both treat face and trunk disease in that nodular frame.

SAP is the wrong door in Canada — Accutane, Epuris, Clarus, Absorica LD and others are marketed. The usual path is labelled prescription + brand pregnancy programme + coverage.

Approval matrix (oral isotretinoin class)

Use the label of the country that will prescribe. A Canadian “recalcitrant acne” sentence is not identical to the US “severe recalcitrant nodular” sentence.

Access by country

• Canada: Dermatologist (or another physician knowledgeable in systemic retinoids and young-adult counselling, per PM). Brand PPP materials and informed consent for all patients. Females of childbearing potential: Conditions of Use + monthly pregnancy tests + 30-day supply + dispense within 7 days. Community pharmacy. Do not ask for SAP. Public plan listing by province: unknown — authorized ≠ funded. Under 12: not recommended.
• United States: Clinician enrolled in iPLEDGE REMS; patient enrolled; pharmacy certified. Monthly pregnancy testing and contraception rules for patients who can get pregnant; 30-day maximum supply; 7-day prescription window. Community / specialty pharmacy in the REMS network. Prior authorization still common. Cash price: unknown here.
• United Kingdom: MHRA-labelled Roaccutane (and generics). Specialist / supervised prescribing. Risk-minimisation measures apply; MHRA has updated under-18 process (Jan 2026 guidance removes the second-prescriber requirement while keeping other RMMs) — ask the local dermatology service what is live now.
• EU/EEA: Oral isotretinoin under national MAs + EU PPP. Specialist start. National reimbursement: unknown country-by-country here.
• Australia: ARTG-registered (Roaccutane and other brands as listed). Specialist prescription. PBS listing status unknown.
• Japan: Acne marketing authorisation not found. Isotrex (Jun 2026) is labelled for neuroblastoma, not acne. Do not self-import as the plan.
• If your regulator has not labelled acne use: do not import on your own.

---

What it actually is

Isotretinoin is an oral retinoid (13-cis-retinoic acid). Labels say the exact anti-acne mechanism is unknown; improvement tracks a temporary drop in sebum and smaller sebaceous glands.

It is not:

• Winlevi or Cabtreo
• a topical retinoid
• labelled for moderate acne on the US Absorica/LD indication — it is not
• a drug you start while pregnant or planning pregnancy
• interchangeable brand-to-brand (Epuris ≠ Clarus ≠ Absorica LD ≠ US Absorica; Absorica ≠ Absorica LD even when both say “20 mg”)
• a Canadian SAP product
• “just dry lips” with no programme

US dose (Absorica / Absorica LD USPI): two divided doses daily; Absorica 0.5–1 mg/kg/day (up to 2 mg/kg/day if very severe scarring/trunk); Absorica LD 0.4–0.8 mg/kg/day (up to 1.6 mg/kg/day); 15–20 weeks; with or without meals; swallow whole with a full glass of liquid. Once-daily dosing is not recommended on that label.

Canadian dose (Epuris / Clarus style PM): often start 0.5 mg/kg/day for 2–4 weeks, then maintain 0.1–1 mg/kg/day (exceptionally up to 2 mg/kg/day); typical course 12–16 weeks; take with food (Epuris absorption drops without food). Absorica LD Canada: 0.4–0.8 mg/kg/day with or without food; course 15–20 weeks.

Second courses: wait (US label: generally ≥2 months off; Canadian Epuris/Clarus language often ≥8 weeks off) because acne can keep improving after the last capsule.

---

What the trials showed (plain numbers)

The modern Absorica / Absorica LD / Epuris Canadian labels rest on a large fed, double-blind comparison of a non-micronized isotretinoin product vs another marketed capsule (US PI Study 1; Epuris PM ISOCT.08.01).

Design (labels). Ages 12–54; ≥10 nodules on face and/or trunk; start 0.5 mg/kg/day × 4 weeks then 1 mg/kg/day × 16 weeks; n≈925 randomized.

Week 20 (US PI Table 3 / HC PM):

Many people get deep, lasting clearing from one course. It is still not “everyone clears,” and the registrational frame is severe nodular, not mild comedonal acne.

Research team / Who (from labels and sponsors only).

• US NDA / Absorica LD: Sun Pharmaceutical Industries, Inc. (distributor); manufacturing listed on DailyMed (Galephar / Ohm as applicable).
• Canada: Cipher Pharmaceuticals (Epuris / PEER); Mylan Pharmaceuticals ULC / Viatris (Clarus / CLEAR); Sun Pharma Canada Inc. (Absorica LD / C-A-R-E); Cheplapharm Schweiz GmbH / Xediton (Accutane).
• US REMS operator contact on label: iPLEDGE — www.ipledgeprogram.com / 1-866-495-0654 (programme line, not a clinic booking number).
• Historical Accutane-era pivotals are evidence, not a 2026 enrolment door. Contacts as printed on labels only.

---

Safety a household should actually watch

Pregnancy — absolute. Both FDA and Health Canada: contraindicated in pregnancy. Extremely high risk of major birth defects, miscarriage, premature birth. Contraception 1 month before, during, and 1 month after. Two forms recommended. Do not donate blood during treatment and for 1 month after. Breastfeeding: contraindicated / not recommended on Canadian and US labels (US Absorica/LD: not recommended during and for at least 8 days after last dose; Canadian PMs: do not breastfeed on drug).

Programme difference:

• United States: iPLEDGE REMS — mandatory for all isotretinoin. Prescriber, patient, and pharmacy must be in the system. Patients who can get pregnant: pregnancy tests and contraception rules; max 30-day supply; fill within the 7-day window.
• Canada: Brand pregnancy prevention programmes (PEER / CLEAR / C-A-R-E) + PM Conditions of Use + informed consent for all patients. Monthly negative pregnancy tests for females of childbearing potential before each 30-day script; dispense within 7 days. Same clinical idea, different paperwork.

Psychiatric (on the label). Depression, psychosis, suicidal ideation/attempts/suicide, aggression reported. Screen before and during. Stop and call if mood changes; stopping the drug may not be enough — further mental-health care may be needed. Causal link not established on the Canadian serious-warnings box; US label still requires monitoring.

Inflammatory bowel disease (on the label). Associated with IBD (including regional ileitis) even without prior bowel disease. Abdominal pain, rectal bleeding, or severe diarrhea → stop and call.

Labs (on the label). Before start: fasting lipids (triglycerides), liver tests; Canadian PMs also list renal function and blood glucose. During: lipids until response known (often within ~4 weeks); LFTs periodically. About 25% get triglyceride rises; ~15% enzyme rises in older trial language. Pancreatitis risk rises with very high triglycerides.

Also on label: dry lips/skin/eyes (very common), nosebleeds, back/joint pain (especially in teens), decreased night vision, hearing changes, intracranial hypertension (avoid tetracyclines), serious skin reactions (SJS/TEN — rare), bone density / growth-plate cautions in adolescents, photosensitivity, no waxing / laser / dermabrasion during and for months after.

Under 12: not established / not recommended.

---

Access: what you can actually do

1. This is a labelled, marketed capsule. SAP is the wrong door in Canada.

Health Canada’s Special Access Programme is for drugs not marketed in Canada. Accutane, Epuris, Clarus, Absorica LD and others are marketed. The path is: fit the labelled population, enrol in the right pregnancy programme for your country, get a prescription, then sort payment.

2. Who to see

A dermatologist, or another physician the Product Monograph describes as knowledgeable in systemic retinoids and counselling young adults. In the US, that clinician must also be iPLEDGE-enrolled. Bring: age, pregnancy/contraception status (or that you cannot get pregnant), mental-health history, IBD history, lipid/liver history, bone issues, sport load, full medication list (especially tetracyclines and vitamin A), and which country’s label applies.

3. Script for the visit

Oral isotretinoin is labelled in the US for severe recalcitrant nodular acne in non-pregnant people 12 and older who failed conventional therapy including systemic antibiotics, and only through iPLEDGE. In Canada, brands such as Epuris, Clarus, Absorica LD, and Accutane are labelled for severe nodular and/or inflammatory acne, acne conglobata, or recalcitrant acne unresponsive to first-line therapy, with brand pregnancy-prevention programmes — not SAP. I am 12 or older. My acne is severe / nodular / scarring / truncal as we have documented. I am not pregnant and I understand contraception and monthly labs if I can get pregnant. Can you confirm I fit the labelled population, enrol me in the correct programme (iPLEDGE vs PEER/CLEAR/C-A-R-E), and tell me the realistic funding path — public plan, private insurance, or cash? I understand authorized is not funded, and brands are not interchangeable.

Ask:

1. Do I meet severe / nodular / recalcitrant labelled use — not “moderate because I’m tired of topicals”?
2. Pregnancy programme: iPLEDGE (US) vs which Canadian brand PPP?
3. Baseline labs and monthly follow-up plan?
4. Mood / IBD stop rules?
5. Food rules for this brand (with food vs Absorica LD with-or-without)?
6. Coverage: which plan, which DIN/brand, prior auth language?
7. Do not ask for SAP in Canada for marketed brands.

4. Public coverage: start from “ask the plan,” not from “approved so covered”

• Canada: marketed ≠ listed. Provincial formularies and NIHB for each DIN: unknown. Ask the clinic or pharmacist to check the live formulary for the exact brand. Private insurance often needs prior authorization with the labelled indication wording.
• United States: commercial and public plans commonly require prior auth + iPLEDGE compliance. Cash price: unknown here.
• UK / EU / Australia: specialist path; national reimbursement not confirmed country-by-country here. Licence ≠ subsidy.

NOC / FDA approval ≠ the same cheque everywhere. Repeat it.

5. Private insurance and cash

Ask the clinic to submit prior auth as severe recalcitrant nodular / severe nodular-inflammatory / acne conglobata / recalcitrant acne — isotretinoin — failed conventional therapy, not “hormonal acne” or “cosmetic.” Brand substitution may be blocked because bioavailability differs. No dollar amounts here.

6. Clinical trials

The registrational comparison underlying Absorica/Epuris labels is completed. It is evidence, not a 2026 enrolment door. Search ClinicalTrials.gov with the prescriber only if a new protocol appears; do not travel on a rumour.

7. If the answer is “not a candidate”

Pregnancy, inability to follow the programme, under-12, or acne that is not in the labelled severity frame need a different plan — topicals (including Winlevi / Cabtreo where labelled), antibiotics where appropriate, hormonal therapy where it fits, or Episode 4’s device/oral pipeline. Isotretinoin is not a shortcut around a negative pregnancy test.

---

Bottom line

Oral isotretinoin is a real, labelled systemic retinoid for severe acne that failed conventional therapy — face and back included in the nodular trial frame. In the large labelled comparison, about seven in ten people on drug hit a 90% drop in nodules by week 20. That is why regulators keep it on the market. It is also why pregnancy programmes, monthly labs, and mood/IBD stop rules are not optional paperwork.

The 2026 fight is the map. US: iPLEDGE REMS. Canada: brand PEER / CLEAR / C-A-R-E plus Product Monograph Conditions of Use — not the same system, and not SAP. UK/EU/Australia: labelled with specialist PPP-style controls. Japan acne MA: not found (Isotrex Jun 2026 = neuroblastoma only). Authorized is not funded. Use the label of the country that will prescribe, and the formulary of the plan that will pay.

---

Primary sources

1. DailyMed. ABSORICA (isotretinoin) / ABSORICA LD (isotretinoin). setid 3ef0cff8-19c1-4441-b780-fca6c7ee1615. Label revised Aug 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef0cff8-19c1-4441-b780-fca6c7ee1615
2. FDA label PDF (Absorica/Absorica LD). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021951s029lbl.pdf
3. iPLEDGE REMS. https://www.ipledgeprogram.com / 1-866-495-0654 (as cited on USPI).
4. Health Canada / Cipher. EPURIS Product Monograph (authorization 2025-05-13; Control 290612). https://www.cipherpharma.com/wp-content/uploads/2026/03/Epuris-PM-EN-May13-2025.pdf (also pdf.hres.ca historical PM copies).
5. Mylan/Viatris. CLARUS Product Monograph (revision 27 Nov 2019). https://www.viatris.ca/-/media/project/common/global/global-product-catalog/product-catalog-canada/files/product-resource-files/clarus_pm_en.pdf
6. Sun Pharma Canada. Absorica LD Product Monograph (initial authorization 22 Jun 2023; revision 15 May 2025). https://absoricald.ca/downloads/Product%20Monograph.pdf
7. Health Canada DPD / DHPP. ACCUTANE (DINs 00582344, 00582352); Absorica LD / Epuris / Clarus DIN listings. e.g. https://dhpp.hpfb-dgpsa.ca/dhpp/resource/5129
8. Health Canada. Accutane PM (revision 5 Sep 2025; initial approval 1982-12-02). https://pdf.hres.ca/dpd_pm/00081681.PDF
9. Health Canada. Information update on isotretinoin pregnancy prevention (historical programme framing). https://www.newswire.ca/news-releases/information-update---health-canada-reinforces-the-importance-of-preventing-pregnancy-while-taking-the-acne-drug-isotretinoin-to-avoid-birth-defects-592614361.html
10. MHRA / emc. Roaccutane 10 mg / 20 mg SmPC. https://www.medicines.org.uk/emc/product/100633/smpc
11. GOV.UK Drug Safety Update. Isotretinoin – changes to prescribing guidance and additional risk minimisation measures (under-18 second-prescriber change). https://www.gov.uk/drug-safety-update/isotretinoin-changes-to-prescribing-guidance-and-additional-risk-minimisation-measures
12. EMA. Isotretinoin / Roaccutane referrals (PPP harmonisation; CPMP 25 Apr 2003; Commission Decision 17 Oct 2003). https://www.ema.europa.eu/en/medicines/human/referrals/isotretinoin
13. TGA. Roaccutane ARTG 50839. https://www.tga.gov.au/resources/artg/50839
14. Brand PPP portals (programme materials, not clinic booking): epuris.ca (PEER); clarusclearprogram.ca (CLEAR); AbsoricaLD.ca (C-A-R-E).

---

Not a substitute for a clinician who treats severe acne.